UK Plugs Into ‘Golden Period’ For Medtech Innovation

 
• By Ashley Yeo
  
Generate a summary of this article
Listen to this article
Beta

The “what” and the “how” involved in bringing medical technology to market for adoption by health-care systems is changing fast. The UK is laying the groundwork to be a global medtech innovation champion with two new tools: NHS England’s Long Term Plan and the newly boosted Accelerated Access Collaborative. The AAC's first chief executive, Sam Roberts, has been profiling her role in this prospective UK market access transformation.

AI hand reaches

A lot of health-care industry planning for the future has happened in the ten years since the UK Office for Life Sciences (OLS) was set up as a bridge between the health and business ministries’ areas of responsibility around innovation, clinical research and market access. The OLS was founded to create a virtuous circle, bringing together health and wealth, and including job creation and the development of health technology for patients in the UK, enabling them to swiftly return to being contributors to the economy. (Also see "UK medtech needs to seize moment and make most of OLS" - Medtech Insight, 22 July, 2009.)

More recently, the UK has redoubled its efforts in this direction, releasing the Industrial Strategy in 2017. This was followed...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

SpotifyApple PodcastsWebsite

More from United Kingdom

Global Medtech Guidance Tracker: September 2024

 
• By Vibha Sharma

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.

Biocomposites Fully Acquires SYNICEM And Subiton Lines, Launches NanoBone In UK

 
• By Natasha Barrow

UK-based Biocomposites will begin selling in the UK its next-generation osteoinductive bone graft substitute, NanoBone, which came with its acquisition of Artoss GmbH in June 2023. Meanwhile, the company has purchased remaining shares in the manufacturers of SYNICEM and Subiton antibiotic bone cements and preformed antibiotic-loaded spacers.

Abbott’s Share-Gobbling Aveir DR Leadless Pacing System Introduced To UK

 
• By Natasha Barrow

The firm’s dual-chamber leadless pacemaker system with is expected to be a growth driver for Abbott and already has acquired approximately 30%-40% of market share from Medtronic since its approval by the US FDA in July 2023, according to GlobalData.

Global Medtech Guidance Tracker: August 2024

 
• By Vibha Sharma

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Nearly 80 documents have been posted on the tracker since its last update.

More from Europe

Biocomposites Fully Acquires SYNICEM And Subiton Lines, Launches NanoBone In UK

 
• By Natasha Barrow

UK-based Biocomposites will begin selling in the UK its next-generation osteoinductive bone graft substitute, NanoBone, which came with its acquisition of Artoss GmbH in June 2023. Meanwhile, the company has purchased remaining shares in the manufacturers of SYNICEM and Subiton antibiotic bone cements and preformed antibiotic-loaded spacers.

Abbott’s Share-Gobbling Aveir DR Leadless Pacing System Introduced To UK

 
• By Natasha Barrow

The firm’s dual-chamber leadless pacemaker system with is expected to be a growth driver for Abbott and already has acquired approximately 30%-40% of market share from Medtronic since its approval by the US FDA in July 2023, according to GlobalData.

Amferia Aims To Bring Peptide Hydrogel To Fight Against Antimicrobial Resistance

 
• By Natasha Barrow

Amferia is developing an antimicrobial peptide hydrogel dressing to combat infections in acute wounds in humans and veterinary contexts. Supported by €1.2m of new venture capital financing, the company is planning pivotal clinical studies to support an FDA application later this year and CE mark submission in 2026-2027.